Sharing a few threads on whether molnupiravir (new antiviral on the cusp of approval) risks generating new variants because the mutations it induces may, rarely but possibly, not kill the virus but generate viable variants instead. Many on the FDA panel who voted no raised this.https://twitter.com/CT_Bergstrom/status/1467611446053851145 …
-
-
Right. Though it's not easy to imagine how to get "clarity" on the viral mutagenesis issue: it'll happen (that's how the drug works!), but will it drive functional mutants? Is mutation rate limiting in evolution, or not? ¯\_(ツ)_/¯ More clarity on efficacy would be welcome.
-
Yeah, clearly need more info on efficacy. On the other clarity part: I'm hoping someone will tell us! But the assumption has to be that many people will not complete the course as prescribed, will not quarantine, some will be immunocompromised (especially if it expands globally).
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
1/15